Get the content you want anytime you want.
The European Clinical Congress of Microbiology and Infectious Diseases (ECCMID 2019)

Select coverage from The European Clinical Congress of Microbiology and Infectious Diseases (ECCMID 2019) is included below:

Lack of Agreement Between Fosfomycin Susceptibility Testing Methods Against <i>Pseudomonas</i>
Elizabeth Hirsch, PharmD, and Elizabeth Smith, PharmD candidate, discuss fosfomycin susceptibility testing.
Intra-Abdominal Candidiasis and a Novel Echinocandin
Minh-Hong Nguyen, MD, discusses rezafungin as a potential treatment option for intra-abdominal candidiasis.
The Benefit of Investigator-Initiated Studies
Steven Tong, PhD, discusses the benefit of investigator-initiated studies.
The Echinocandin Era
László Majoros, MD, PhD, discusses how nearly all invasive fungal infections are being treated with echinocandins.
Bacteriophage Therapy as Alternative Treatment
Tristan Ferry, MD, PhD, discusses bacteriophage therapy as an alternative treatment for certain patients.
ASPECT-NP: 3-Gram Dose of Ceftolozane/Tazobactam
Marin Kollef, MD, discusses what makes the 3-gram dose regimen of ceftolozane/tazobactam unique.
What's Next for CAMERA2?
Steven Tong, PhD, discusses the next steps for research on combination therapy for MRSA bacteremia.
Takeaways from ECCMID 2019: Part 2
Experts from the fields of microbiology and infectious disease share their biggest takeaways and highlights from ECCMID 2019.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?